[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dexamethasone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dexamethasone":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,52,79,106,133,162,191,216,240,264,292,315,335,370],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644172","phase-3-liposomal-bupivacaine-plus-plain-bupivacaine-versus-dexamethasone-plus-plain-bupivacaine-in-the-supraclavicular-brachial-plexus-block-in-patients-with-risk-factors-for-severe-acute-postoperative-pain-100644172",false,"NCT07665762","Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain","Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain: a Randomized Controlled Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologist (ASA) status I-III\n* Age 18-90 years old\n* Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)\n* Informed consent obtained\n* Patients identified to be at an elevated risk of suffering from poor postoperative pain control. Patients with one or more of the following risk factors:\n\n  * Severe preoperative pain: defined as worse numerical rating scale (NRS) pain score equal or higher than 6\u002F10 with arm movements at day before surgery.\n  * Preoperative use of opioid: use of strong opioids such as morphine, oxycodone\n  * Depressive symptoms: Patient health questionnaire (PHQ-9) score of 10 or above\n  * Anxiety symptoms: General Anxiety Disorder (GAD-7) score of 10 or above\n  * Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant\n\nExclusion Criteria:\n\n* Revision surgery\n* Previous fractures or surgery in the affected distal radius\n* Surgery involving more than the affected arm\n* Cases with baseline (pre-injury) QuickDASH score worse (higher) than 10 out of 100\n* Respiratory compromise (requires long term oxygen)\n* History of seizures\n* Pre-existing neurological disorder\u002Fdeficit\n* Alcohol or substance abuse\n* Impaired mental state\n* Local infection\n* Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids\n* Impaired renal function (defined as effective glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m2\n* Impaired liver function (defined as plasma bilirubin over 34μmol\u002FL; international normalized ratio \\[INR\\] ≥1.7, alanine aminotransferase \\[ALT\\] over 100U\u002FL, aspartate aminotransferase \\[AST\\] over 100U\u002FL)\n* Coagulopathy (platelet count \\\u003C100,000\u002Fml and\u002For INR ≥ 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB\n* Pregnancy\n* Patient refusal for regional nerve blocks\n* Patient refusal to join the clinical trial\n* Patient unable\u002Funwilling to attend post-op rehabilitation programme","ALL","18 Years","90 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The supraclavicular brachial plexus block (BPB) is a frequently used anaesthetic method for upper limb surgeries, including distal radial fracture surgery. Adding liposomal bupivacaine to BPB has shown promise in enhancing postoperative pain control. A previous randomized controlled trial demonstrated that it reduced pain scores and OBAS compared to plain bupivacaine alone, especially on postoperative day (POD) 1. Adding adjuncts to non-liposomal local anaesthetics can also enhance and prolong postoperative pain relief. The effectiveness of liposomal bupivacaine compared to adjuncts like dexamethasone and dexmedetomidine remains unclear. Since liposomal bupivacaine is more expensive, it is crucial to compare its analgesic efficacy with these alternatives. A randomized controlled trial comparing liposomal bupivacaine versus dexamethasone in the interscalene BPB for shoulder surgery found that liposomal bupivacaine resulted in statistically significantly lower pain scores and less pain interference in the Brief Pain Inventory, although the reduction was not considered clinically relevant. Its high cost may therefore limit its routine use unless specific clinical contexts where its efficacy is maximized are identified. Notably, patients with risk factors like psychological factors, preoperative pain, and prior analgesic use may benefit most from its application.\n\nA randomized controlled trial to compare the analgesic efficacy of liposomal bupivacaine plus plain bupivacaine versus dexamethasone plus plain bupivacaine in supraclavicular BPB for patients at higher risk of poor acute pain control post distal radial fracture surgery will be conducted. Patients with severe preoperative pain, opioid use, depressive symptoms, anxiety symptoms, and\u002For higher energy and high-grade fracture cases will be selected. The primary outcome measured is the intensity of acute postoperative pain with movement in the first 48 hours after surgery. Important secondary outcomes include pain intensity at rest, opioid consumption, OBAS scores, chronic pain, and upper limb functionality.",[27,28,29,30,31,32],"Pain, Postoperative","Liposomal Bupivacaine","Dexamethasone","Supraclavicular Brachial Plexus Block","High Risk Factors","Distal Radial Fracture",[34,35,36,37,38],"supraclavicular brachial plexus block","liposomal bupivacaine","dexamethasone","distal radial fracture","pain","NOT_YET_RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-24","ACTUAL",{"date":45,"type":21},"2026-06-15",{"date":47,"type":21},"2029-03-01",{"name":49,"class":50},"The University of Hong Kong","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100623905","phase-4-dosing-of-steroids-for-acute-asthma-given-in-the-emergency-department---a-pilot-randomised-feasibility-trial-of-dexamethasone-in-children-100623905","NCT07402707","Dosing of Steroids for Acute Asthma Given in the Emergency Department - a Pilot Randomised Feasibility Trial of Dexamethasone in Children","DOSAGE","Inclusion Criteria:\n\n* Children aged 4-15 years (inclusive) presenting to the ED with an asthma exacerbation, where oral steroids are recommended by Trust\u002FNational guidelines.\n* Children whose parents\u002Fcarers do not speak English will also be eligible provided they speak one of the common languages where an interpreter and Information Sheets are available (Slovakian, Arabic and Urdu).\n\nExclusion Criteria:\n\n* Children who have been treated with oral or IV steroids in the last 2 weeks.\n* Hypersensitivity to the study drug.\n* Children who have concomitant stridor.\n* First episode of wheezing (not previously diagnosed as asthma).\n* Children with known difficult asthma who receive longer courses of steroids as standard.\n* Life threatening episode of asthma.\n* Children with other conditions that require them to have steroids when unwell.\n* Children who are involved in current research or have recently been involved in research prior to recruitment","4 Years","15 Years",{"count":62,"type":21},104,[64],"PHASE4","Steroids given by mouth are an important first line treatment for children presenting with asthma attacks. Dexamethasone is the steroid used in some emergency departments (EDs) because of the need for a single dose and as it is well tolerated. The dose of dexamethasone in treating asthma attacks is not clearly established. This study compares two different doses of dexamethasone in children presenting with an asthma attack. Investigators will compare the effect of two different doses in reducing the need for a repeat prescription of steroids for an asthma attack in the 2 weeks after the first treatment. The investigators will also look at how often children attend the ED or their GP after being given treatment as well as the acceptability to parents and children. Although this study may provide an answer to the question of whether the different doses have the same effect, the investigators believe that a larger study will be needed to provide robust generalisable evidence, as well as to ensure that the outcomes are truly what matters to parents, children and healthcare professionals. This study will provide valuable information to enable a larger study to be undertaken.",[67,29],"Acute Asthma",[29],"RECRUITING","2026-04-20",{"date":72,"type":43},"2026-04-23",{"date":74,"type":43},"2026-02-23",{"date":76,"type":21},"2026-08-31",{"name":78,"class":50},"Sheffield Children's NHS Foundation Trust",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100617890","effect-of-dexamethasone-on-plasma-levels-of-bupivacaine-and-dexamethasone-after-a-single-injection-interscalene-nerve-block-100617890","NCT07324499","Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone After a Single-injection Interscalene Nerve Block.","Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone Following a Single-injection Interscalene Nerve Block: A Randomized Controlled Study","Inclusion Criteria:\n\n\\- ASA I-II patients, with a body mass index (BMI) between 20 and 34 kg\u002Fm2 scheduled for shoulder surgery requiring single-needle interscalene block\n\nExclusion Criteria:\n\n\\- Chronic opioid use, liver failure, kidney failure, allergy to protocol drugs",{"count":87,"type":21},40,[89],"NA","Recent studies have highlighted the comparative advantages of perineural dexamethasone, particularly regarding its safety profile and its ability to prolong analgesia in various peripheral nerve blocks. A recent systematic review demonstrated that perineural administration of dexamethasone significantly extends the duration of analgesia compared to intravenous administration.\n\nThe mechanism of action of perineural dexamethasone remains unclear. Moreover, there is a lack of research comparing the systemic absorption of local anesthetics administered perineurally with or without dexamethasone, and the systemic absorption and bioavailability of dexamethasone when used as a perineural adjuvant have not been studied.\n\nObjective: This study aims to compare plasma concentrations of bupivacaine following a single-shot interscalene block with dexamethasone administered either perineurally or intravenously.\n\nMethodology: A prospective, randomized, double-blind trial will be conducted involving 40 patients undergoing shoulder surgery requiring a single-shot interscalene block. Each patient will receive 20 mL of 0.25% bupivacaine combined with 8 mg of dexamethasone administered either perineurally or intravenously. Venous blood samples (5 mL) will be collected at 5, 10, 20, 40, 80, 120, and 240 minutes post-block, and one sample at discharge, to measure plasma concentrations of both enantiomers of bupivacaine (D(+)-bupivacaine and L(-)-bupivacaine) and dexamethasone.\n\nOutcomes: The study will compare plasma levels of bupivacaine between groups, characterize the pharmacokinetics of bupivacaine and dexamethasone, and assess block duration and opioid consumption.",[92,93,29,94],"Pain","Interscalene Blocks","Bupivacaine",[29,94,92,96],"Interscalene blocks","2025-12-30",{"date":99,"type":43},"2026-01-07",{"date":101,"type":21},"2026-03-01",{"date":103,"type":21},"2027-12-01",{"name":105,"class":50},"Pontificia Universidad Catolica de Chile",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":51},"100618308","dexamethasone-dexmedetomidine-and-their-combination-on-post-op-git-function-measured-by-i-ffed-score-post-laparoscopic-cholecystectomy-100618308","NCT07329933","Dexamethasone, Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy","Effect of Dexamethasone, Dexmedetomidine and Their Combination on Postoperative Gastrointestinal Function Measured by I-FEED Score After Elective Laparoscopic Cholecystectomy Surgery: a Randomized Controlled Trial","GIT","Inclusion Criteria:\n\n\\- . Age 18-65 years. 2. American Society of Anesthesiologists (ASA) physical status I or II. 3. Scheduled for elective laparoscopic cholecystectomy surgery under general anesthesia.\n\n4\\. Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to any study drug (dexamethasone, dexmedetomidine, or placebo).\n\n  2\\. Pre-existing gastrointestinal motility disorders (e.g., gastroparesis, inflammatory bowel disease).\n\n  3\\. Chronic use of opioids, steroids, or antiemetics. 4. History of severe cardiac disease (e.g., high-grade AV block, severe bradycardia).\n\n  5\\. Uncontrolled diabetes mellitus (HbA1c \\> 8.0%). 6. Emergency surgery or conversion to open surgery. 7. Pregnancy or breastfeeding. 8. Morbid obesity (BMI \\>40). 9. Severe hepatic or renal dysfunction.","65 Years",{"count":116,"type":21},160,[89],"The goal of this clinical trial is to learn the effect of Dexamethasone and Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy\n\nWhat medical problems do participants have when taking Dexamethasone and Dexmedetomidine? Researchers will compare Dexamethasone and Dexmedetomidine and Their Combination to a placebo (a look-alike substance that contains no drug) to see the effect on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexmedetomidine 0.5 mcg \u002Fkg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg\u002Fkg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia",[120,121,29,122,123],"GIT Function","Cholecystectomy, Laparoscopic","Dexmedetomidine","I-FEED Score","2025-12-29",{"date":126,"type":43},"2026-01-09",{"date":128,"type":21},"2025-12-15",{"date":130,"type":21},"2026-06-01",{"name":132,"class":50},"Benha University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":51},"100603669","dexamethasone-versus-magnesium-sulphate-as-an-adjuvant-to-bupivacaine-in-ultrasound-guided-erector-spinae-plane-block-for-postoperative-analgesia-in-elective-caesarean-section-under-spinal-anesthesia-100603669","NCT07139522","Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia","The Efficacy of Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age from 18 to 35 years.\n* Full-term, singleton, pregnant women.\n* American Society of Anesthesiologists (ASA) physical status II.\n* Scheduled for elective cesarean delivery under spinal anesthesia.\n\nExclusion Criteria:\n\n* Refusal of the patient.\n* Emergency caesarean sections.\n* Patients having chronic diseases as asthma, cardiovascular disorders (Significant arrhythmias, Severe Valvular diseases, congenital heart diseases, ischemic heart disease, cardiomyopathy, deep venous thrombosis ,and pulmonary embolism)\n* Renal impairment (Creatinine level ≥ 2mg\u002Fdl, urea ≥ 25mg\u002FdL), liver impairment \\[Alanine aminotransferase (ALT) \\\u003C 45 U\u002FL, Aspartate aminotransferase (AST) \\\u003C 45 U\u002FL\\].\n* Allergy to the drug enrolled in the study.\n* Body mass index (BMI) ≥ 35 kg\u002Fm2.\n* Hypertensive disorders of pregnancy.\n* Contraindication to spinal anesthesia, such as coagulopathy \\[platelet count \\\u003C150.000, international normalized ratio (INR) \\> 1.2\\], or local infection.\n* Requirement for conversion to general anesthesia after spinal anesthesia will also be excluded.","35 Years",{"count":142,"type":21},150,[89],"This study aims to compare the efficacy of adding dexamethasone and magnesium sulfate as an adjuvant to bupivacaine in bilateral erector spinae block in postoperative pain control in patients undergoing caesarean section under spinal anesthesia.",[29,146,147,148,149,150,151,152],"Magnesium Sulphate","Adjuvant","Ultrasound","Erector Spinae Plane Block","Postoperative Analgesia","Cesarean Section","Spinal Anesthesia","2025-08-18",{"date":155,"type":43},"2025-08-24",{"date":157,"type":43},"2023-12-01",{"date":159,"type":21},"2025-12-01",{"name":161,"class":50},"Cairo University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":18,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":51},"100378566","intraoperative-blood-pressure-management-and-dexamethasone-in-lung-cancer-surgery-100378566","NCT04209218","Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery","Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged \\>50 years but \\\u003C90 years.\n* Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \\>2 hours.\n* Agree to participate in this study and sign the informed consent.\n\nExclusion Criteria:\n\n* Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery.\n* Recurrent or metastatic lung cancer.\n* History of cancer or complicated with cancer in other organs.\n* Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation.\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg); or requirement of vasopressors to maintain blood pressure.\n* Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months.\n* Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy).\n* Any other circumstances considered unsuitable for study participation by attending physicians or investigators.","50 Years",{"count":171,"type":21},1988,[89],"Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.",[175,176,177,29,178,179],"Lung Cancer","Surgery","Blood Pressure Management","Overall Survival","Postoperative Complications",[175,181,177,29,178,179],"Radical Resection","2025-07-29",{"date":184,"type":43},"2025-07-31",{"date":186,"type":43},"2020-04-07",{"date":188,"type":21},"2029-12",{"name":190,"class":50},"Peking University First Hospital",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":51},"100599563","dexamethasone-versus-metoclopramide-for-prophylaxis-of-nausea-and-vomiting-after-cataract-surgery-100599563","NCT07086118","Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery","Efficacy of Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery: A Double-blind Randomized Controlled Study","Inclusion Criteria:\n\n* Age: 40-80 years, both sexes.\n* ASA physical status class I to III.\n\nExclusion Criteria:\n\n* history of motion sickness\n* patients with gastrointestinal disorders or gastro-oesophageal reflux\n* patients taking medications with known antiemetic activity\n* previous postoperative vomiting\n* allergy to bupivacaine\n* allergy to metoclopramide or dexamethasone","40 Years","80 Years",{"count":201,"type":21},210,[89],"Postoperative nausea and vomiting (PONV) is a common consequence of ambulatory surgery, affecting up to 80% of high-risk patients and 20-30% overall. Despite being widespread, a prior survey found that patients are more averse to PONV than pain and other significant postoperative problems. Furthermore, even mild cases of PONV can have serious repercussions, such as postanesthesia care unit (PACU) workflow disruption, delayed discharges, higher medical costs, and lower patient satisfaction.PONV following intraocular surgery can be unpleasant and may lead to serious complications including suprachoroidal hemorrhage (SCH). SCH is a potentially serious condition that occurs when the posterior ciliary arteries or vortex veins burst, resulting in blood in the suprachoroidal region.\n\nThe hypothesis is that dexamethasone will lower the incidence of PONV after cataract surgery when compared with metoclopramide.",[205,29],"Cataract",[36,207],"cataract surgery","2025-07-18",{"date":210,"type":43},"2025-07-25",{"date":212,"type":43},"2025-05-01",{"date":159,"type":21},{"name":215,"class":50},"Alexandria University",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100383003","restrictive-use-of-dexamethasone-in-glioblastoma-100383003","NCT04266977","Restrictive Use of Dexamethasone in Glioblastoma","RESDEX","Inclusion Criteria:\n\n* Newly diagnosed supratentorial contrast enhancing lesion suspicious of glioblastoma without major mass effect, amenable to surgical resection\n* Age 18 - 90 years\n* Midline Shift ≤ 3mm\n* GCS ≥ 14\n* NIHSS ≤ 3\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Infratentorial lesions, brainstem lesions, multifocal lesions\n* Therapy with steroids for \\>1 day before inclusion\n* Need for treatment with steroids due to any other disease\n* Contraindications to the administration of Dexamethasone\n* Pregnancy or breastfeeding",{"count":224,"type":21},50,[89],"The administration of steroids, most commonly dexamethasone (DEX), has established as standard of care during treatment of glioblastoma (GBM) and is widely used during the entire course of the disease including pre- and postoperative management, chemo- and radiotherapy. The primary purpose is to reduce tumor-associated vasogenic edema and to prevent or treat increased intracranial pressure. However, steroids are also linked to a multitude of adverse side effects that may affect survival of GBM patients such as major immunosuppression. The use of steroids during radiotherapy is associated with reduced overall- and progression-free survival and has been identified as an independent poor prognostic factor. Despite these findings, the suspicion of GBM often triggers the administration of DEX in routine clinical practice, regardless of neurological symptoms, tumor size, or extension of cerebral edema. The purpose of this study is to assess whether selected GBM patients can be treated safely with a restrictive DEX regimen from referral to the neurosurgical center until discharge.\n\nThe primary objective is to determine the failure rate of a restrictive DEX regimen defined as edema or mass effect leading to any of the following: GCS deterioration ≥ 2 points, NIHSS increase ≥ 3 points, increase of midline Shift ≥ 2mm, or any surgical rescue procedure for increasing mass effect.",[228,29,229],"Glioblastoma","Steroids","2025-07-03",{"date":232,"type":43},"2025-07-09",{"date":234,"type":43},"2020-05-08",{"date":236,"type":21},"2028-04",{"name":238,"class":50},"Insel Gruppe AG, University Hospital Bern",4,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":51},"100526359","dexmedetomidine-ozone-and-dexamethasone-local-injection-in-carpal-tunnel-syndrome-for-pain-relief-100526359","NCT06133712","Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief","A Comparative Study Between Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Long- Term Pain Relief","Inclusion Criteria:\n\n* Age from 20 to 60 years.\n* Both sexes.\n* Patients with ultrasonographic evidence of mild-to-moderate carpal tunnel syndrome (CTS).\n* Inclusion criteria will include numbness and pain in the median nerve (MN) distribution persisting for minimum of 3 months , nerve conduction studies (NCS) consistent with carpal tunnel syndrome (CTS) as per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines, and an median nerve (MN) cross-sectional area (CSA)at the wrist \\>12 mm2 suggesting mild-to-moderate CTS forms.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with severe symptoms and signs of CTS as identified per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines,\\[14\\] as this is an indication for surgery,\n* Patients who show improvement on medical treatment,\n* Previous surgical or injectional CTS treatment,\n* Pregnancy ,co existence of brachial plexopathy, or thoracic outlet syndrome, polyneuropathy, radiculopathy and peripheral nerve lesion in upper limb.\n* Severe cardiovascular disease\n* Morbid obese patients (body mass index (BMI) of \\>35 kg\u002Fm2)\n* Infection at site of injection.\n* Bleeding diathesis.\n* History of thyroid deficiency, uncontrolled diabetes mellitus , rheumatoid arthritis and history of glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* History of Ozone or Dexmedetomidine allergy.\n* End stage renal and hepatic disease.\n* History of inflammatory joint , connective tissue disorders, , burns, any local tissue contractures and history of wrist trauma.\n* Patients who will not consent to completing The visual analogue scale (VAS) for pain or nerve conduction study before and after injection.","20 Years","60 Years",{"count":250,"type":21},135,[89],"The aim of the present study is to compare the analgesic efficacy of Dexmedetomidine, Ozone and Dexamethasone regional injection in carpal tunnel syndrome.",[254,122,255,29],"Carpal Tunnel","Ozone","2025-05-22",{"date":258,"type":43},"2025-05-29",{"date":260,"type":43},"2023-11-01",{"date":159,"type":21},{"name":263,"class":50},"Tanta University",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":271,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":276,"conditions":277,"keywords":280,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":51},"100591472","phase-2-effect-of-pre-medication-with-anti-inflammatory-drugsibuprofen-and-dexamethasoneon-post-endodontic-pain-100591472","NCT06980870","Effect of Pre-medication With Anti-inflammatory Drugs(Ibuprofen and Dexamethasone)on Post-Endodontic Pain","Effect of Pre-medication With Anti-inflammatory Drugs(Ibuprofen and Dexamethasone)on Post-Endodontic Pain With Symptomatic Irreversible Pulpitis","Inclusion Criteria:\n\n1. Permanent teeth with acutely inflamed pulp without swelling or draining sinus.\n2. Patients of either gender aged between 18-50 years old.\n3. Systemically healthy patients.\n4. Patients who agree to attend for recall appointments and provide a written consent.\n\nExclusion Criteria:\n\n1. Patients on preoperative analgesics and antibiotics.\n2. Teeth with calcified canals and previously treated teeth.\n3. Pregnant and lactating mothers.\n4. Patients who are immunocompromised, anxious and mentally handicapped.\n5. Patients who are allergic to any of the test medications.",true,{"count":273,"type":21},130,[275],"PHASE2","Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain with symptomatic irreversible pulpitis",[278,279,29],"Post-endodontic Pain","Ibuprofen",[281,282,36],"post-endodontic pain","ibuprofen","2025-05-17",{"date":285,"type":43},"2025-05-20",{"date":287,"type":43},"2025-02-15",{"date":289,"type":21},"2025-06-15",{"name":291,"class":50},"Armed Forces Institute of Dentistry, Pakistan",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":4},"100573759","phase-3-dapagliflozin-versus-dexamethasone-role-in-pre-operative-management-of-non--diabetic-brain-tumor-patients-100573759","NCT06750458","Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients","Comparative Study Between Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients","Inclusion Criteria:\n\n* Males \\& females.\n* Age: between 18 and 75 years old.\n* Pre-operative non-diabetic glioma patients on levetiracetam. • Diagnosis will be confirmed by:\n\n  * The initial clinical examination.\n  * Magnetic resonance imaging of the brain (MRI) with contrast.\n\nExclusion Criteria:\n\n* Age: \\> 75 years old, and \\\u003C18 years old.\n* Breast feeding female. • Pregnant female.\n* eGFR\\\u003C 30 mL\u002Fminute\u002F1.73 m2.\n* Patients with diabetes mellitus.\n* Patients with diabetic ketoacidosis.\n* Patients with urinary tract infection.\n* Dehydrated patients till normalized.\n* Lower limb amputation patients.\n* SGLT2 inhibitors hypersensitivity.\n* Severe hepatic patients (child-plug score class-c).","75 Years",{"count":301,"type":21},75,[24],"The aim of the study is to compare between the role of dapagliflozin versus dexamethasone in pre-operative management of non-diabetic glioma patients on levetiracetam as anti-seizure drug.",[305,306,29],"Glioma","Dapagliflozin (Forxiga)","2025-04-20",{"date":309,"type":43},"2025-04-22",{"date":311,"type":21},"2025-08-20",{"date":313,"type":21},"2026-12-20",{"name":263,"class":50},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":271,"sex":16,"minAge":17,"maxAge":299,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":51},"100536289","effect-of-dexamethasone-adjuvant-in-combined-supraclavicular-block-and-suprascapular-block-versus-interscalene-block-in-patients-undergoing-shoulder-arthroscopy-100536289","NCT06262893","Effect of Dexamethasone Adjuvant in Combined Supraclavicular Block and Suprascapular Block Versus Interscalene Block in Patients Undergoing Shoulder Arthroscopy","Inclusion Criteria:\n\n* ASA status 1,2.\n\n  * Age 18 years or older\n  * Elective shoulder arthroscopic surgery under general anesthesia and nerve block performed preoperatively.\n\nExclusion Criteria:\n\n* • Patient refusal\n\n  * Serious cardiac arrhythmias (including atrial fibrillation) or unstable coronary artery disease.\n  * Use of drugs that act on the autonomic nervous system (including β- blockers).\n  * Coagulation disorders..\n  * Anatomical disorders and\u002For neuropathic disease.\n  * BMI above 40.\n  * History of substance abuse.\n  * Chronic use of psychotropic and\u002For opioid.\n  * History of psychiatric diseases needing treatment.\n  * Allergy to any drug in the study protocol.\n  * Failure of nerve block performed in the preoperative block room when tested prior to entering the operating room (i.e. lack of loss of sensation to ice at the shoulder incision level).",{"count":322,"type":21},60,[89],"In this study the investigators aim to compare the effect of the suprascapular- supraclavicular nerve block in association with dexamethasone to that of the interscalene brachial plexus block on analgesic effect during arthroscopic shoulder surgery, as postoperative pain scores ,postoperative consumption of analgesic rescue medications and diaphragmatic excursion assessment.",[326,29],"Shoulder Arthroscopy Blocks","2025-04-17",{"date":309,"type":43},{"date":330,"type":43},"2024-02-25",{"date":332,"type":21},"2026-01-01",{"name":334,"class":50},"Assiut University",{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":271,"sex":342,"minAge":17,"maxAge":140,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":354,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":51},"100564074","phase-4-immunomodulatory-effects-of-dexamethasone-tocilizumab-and-anakinra-during-experimental-human-endotoxemia-100564074","NCT06624436","Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia","DEDICATE-LPS","Inclusion Criteria:\n\n* Male subjects aged ≥18 and ≤35 years\n* Body mass index (BMI) ≥18 and ≤30 kg\u002Fm2\n* Healthy (as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram and routine clinical laboratory parameters)\n* Able to comprehend and sign the Information letter and Informed Consent (IC) prior to enrolment in the study.\n\nExclusion Criteria:\n\n* Use of any prescription medication or over-the-counter non-steroidal anti-inflammatory drugs\n* Known anaphylaxis or hypersensitivity to any (non-)investigational products or their excipients\n* History of chronic headache or previous post-dural puncture headache (PDPH)\n* History or signs of severe atopic syndrome (asthma, rhinitis with medication and\u002For eczema)\n* History of any disease associated with immune deficiency\n* History of cancer in the last 5 years (excluding localised skin cancer or carcinoma in situ)\n* History or signs of haematological disease\n* History or signs of thromboembolic disorders\n* History of peptic \u002F gastric ulcer disease\n* History of psychiatric disorders\n* Thrombocytopenia (\\<150\\*109\u002FmL) or anaemia (\\<8.0 mmol\u002FL)\n* History, signs or symptoms of cardiovascular disease, in particular:\n\n  * Prone to vagal collapse\n  * History of atrial or ventricular arrhythmia\n  * Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrio-ventricular block or a complete left bundle branch block\n  * Hypertension (defined as RR systolic \\> 160 or RR diastolic \\> 90 mmHg)\n  * Hypotension (defined as RR systolic \\< 100 or RR diastolic \\< 50 mmHg)\n* Renal impairment (defined as plasma creatinine \\>120 μmol\u002FL)\n* Liver enzyme abnormalities (above 2x the upper limit of normal)\n* Signs of infection (CRP \\> 20 mg\u002FL, white blood cells \\> 12x109\u002FL or\n\n  * lt; 4x109\u002FL)\n* Clinically significant acute illness, including infections or trauma, within 1 month prior to the first LPS challenge\n* Previous (participation in a study with) endotoxin (LPS) administration\n* Participation in an experimental intervention or drug trial within 3 months prior to the first LPS challenge\n* Any vaccination or blood donation within 1 month prior to the first LPS challenge\n* Recent hospital admission or surgery with general anaesthesia within 3 months prior to the first LPS challenge\n* Use of recreational drugs within 2 weeks prior to the first LPS challenge\n* Suspected of not being able to comply with the trial protocol\n* Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and\u002For take part in the study","MALE",{"count":344,"type":21},52,[64],"The goal of this clinical trial is to investigate the immunomodulatory effects of the drugs dexamethasone, tocilizumab and anakinra in healthy male subjects aged 18 to 35 undergoing experimental endotoxemia. The main questions it aims to answer are:\n\n* What are the effects of these drugs on the development of immunoparalysis in a repeated human endotoxemia model?\n* What is the extent of the neuroinflammatory response and how do these drugs affect neuroinflammation in a repeated human endotoxemia model?\n\nResearchers will compare these drugs to a placebo (a look-alike substance that contains no drug).\n\nParticipants will visit the Intensive Care research department on two or five occasions (screening included):\n\n* The intervention group will receive an LPS challenge twice, with a week in between. Before the first LPS challenge, one of the described drugs will be administered. Blood, saliva and tear fluid will be collected regularly during the LPS challenge. Cerebrospinal fluid will also be collected through a catheter in the spinal cord.\n* The control group will not receive an LPS challenge or drug administration and will have only one study day. During this day, blood, saliva, tear fluid and cerebrospinal fluid will be collected as regularly as during the LPS challenge of the intervention group.\n\nDuring an LPS challenge, the investigators mimic blood poisoning by giving an endotoxin, also called LPS. This is a small part of the cell wall of a bacteria. This will cause transient flu-like symptoms for 3-4 hours.",[348,349,350,351,352,29,353],"Sepsis","Neuroinflammatory Response","Immunosuppresion","Endotoxemia","Anakinra","Tocilizumab",[348,355,356,357,352,29,353,358,359,360],"Immunosuppression","Systemic inflammation","Neuroinflammation","Human endotoxemia","Immunoparalysis","Hyperinflammatory response","2025-04-01",{"date":363,"type":43},"2025-04-04",{"date":365,"type":43},"2024-10-24",{"date":367,"type":21},"2025-12",{"name":369,"class":50},"Radboud University Medical Center",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":377,"minAge":17,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":383,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":51},"100495497","phase-4-evaluating-the-effect-of-intravenous-dexamethasone-on-the-duration-of-spinal-anesthesia-after-cesarean-delivery-100495497","NCT05731960","Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia After Cesarean Delivery","A Randomized Controlled Trial Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia as Part of a Multimodal Antiemetic Strategy for Enhanced Recovery After Cesarean Delivery","Inclusion Criteria:\n\n* Non-emergent Caesarean Delivery with planned spinal anesthesia\n* American Society of Anesthesia physical status class \\\u003C III\n* Age ≥18 years\n* Term gestational age (≥37weeks)\n* Singleton pregnancy\n* Moderate English language fluency\n\nExclusion Criteria:\n\n* Obesity (BMI ≥ 45kg\u002Fm2)\n* Height \\\u003C 5'0\"\n* Patients with significant obstetric or neonatal co-morbidities (i.e., severe maternal cardiac disease, preeclampsia, fetal anomalies)\n* Opioid tolerance or sensitivity\n* Intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)\n* Contraindication to neuraxial analgesia (i.e., coagulopathy, infection, neuropathy)\n* Abnormal spinal anatomy (i.e., severe scoliosis, spina bifida, spinal instrumentation)\n* Use of chronic steroids\n* A physical or psychiatric condition which impairs cooperation","FEMALE",{"count":379,"type":21},192,[64],"The goal of this clinical trial is to determine the effects of intravenous (IV) dexamethasone on spinal anesthesia in healthy women having an elective Cesarean delivery (CD) at the IWK Health Centre. The main questions it aims to answer are:\n\n1. What effect does IV dexamethasone have on the resolution of motor blockade in patients having spinal anesthesia for elective CDs?\n2. What effect does IV dexamethasone have on the sensory recovery of spinal blockade, the total hydromorphone requirement in the first 24 h postoperatively, the incidence of pruritis perioperatively, and the incidence of nausea and vomiting?\n\nThe spinal anesthesia technique will be standardized and will be administered as per routine care at IWK Health. Computer generation will randomize patients to either Group SD, who will receive IV dexamethasone, or group SM who will receive IV metoclopramide, an alternative anti-emetic, immediately after spinal anesthesia by the attending anesthesia provider. Each patient will receive ondansetron, a second anti- emetic as recommended for Enhanced Recovery After Surgery (ERAS) protocol. Participant sensation, pain, nausea, pruritus, and motor blockade will be assessed in recovery. The patient's sensation and Bromage score will be assessed every 15 minutes until sensation is reached at L3 and a Bromage score of 4 is achieved.\n\nThe investigators will determine if there is a difference between groups regarding motor blockade, the length of time of spinal anesthesia, and side effects after CD.",[152,29],[384,36,385],"spinal anesthesia","motor block","2024-07-05",{"date":388,"type":43},"2024-07-08",{"date":390,"type":43},"2023-03-06",{"date":367,"type":21},{"name":393,"class":50},"IWK Health Centre"]